Sitravatinib: Additional Phase I data

Data from 52 patients with advanced solid tumors in an open-label, dose-escalation, U.S. Phase I/Ib

Read the full 157 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE